Apovincaminsaeure-ethylester | 1027512-02-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Eburnan型生物碱
• 英文名称: Apovincaminsaeure-ethylester
• 英文别名: eburnamenine-14-carboxylic acid ethyl ester；Ethyl eburnamenine-14-carboxylate；ethyl 15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
• CAS: 1027512-02-2
• 化学式: C₂₂H₂₆N₂O₂
• mdl: MFCD00211233
• 分子量: 350.461
• InChiKey: DDNCQMVWWZOMLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl (2Z)-3-(1-ethyl-3,4,6,7,12,12b-hexahydro-2H-indolo[2,3-a]quinolizin-1-yl)-2-hydroxyiminopropanoate 生成 Apovincaminsaeure-ethylester
  参考文献：
  名称：

  SZANTAY, CSABA;SZABO, LAJOS;KALAUS, GYORGY;UREIDL, JANOS;CZIBULA, LASZLO;+

  摘要：

  DOI：

文献信息

• KATSUBE, JUNKI;ONO, KEIICHI;KAWAKAMI, HAJIME
  作者：KATSUBE, JUNKI、ONO, KEIICHI、KAWAKAMI, HAJIME

  DOI：——

  日期：——
• VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH
  申请人：Ellies Debra

  公开号：US20100003324A1

  公开（公告）日：2010-01-07

  The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.
• US8198292B2
  申请人：——

  公开号：US8198292B2

  公开（公告）日：2012-06-12
• [EN] VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR PROMOTING BONE GROWTH<br/>[FR] DÉRIVÉS DE LA VINPOCÉTINE ET DE L'ÉBURNAMONINE FAVORISANT LA CROISSANCE OSSEUSE
  申请人：OSTEOGENEX INC

  公开号：WO2010002835A2

  公开（公告）日：2010-01-07

  The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer.
• [EN] TREATMENT OF SYNUCLEINOPATHIES<br/>[FR] TRAITEMENT DE SYNUCLÉINOPATHIES
  申请人：DEUTSCHES ZENTRUM FUER NEURODEGENERATIVE ERKRANKUNGEN E V DZNE

  公开号：WO2018069312A1

  公开（公告）日：2018-04-19

  The present invention relates to a modulator of PDE1A and/or PDE1C for use as a medicament, in particular for use in the prevention or treatment of synucleinopathies, such multiple system atrophy, dementia with Lewy bodies, Parkinson's disease, pure autonomic failure, rapid eye movement sleep behavior disorder or inherited synucleinopathies caused by mutations or multiplications of the SNCA gene, or synucleinopathies caused by mutations in other genes including, but not limited to GBA, LRRK2 and PARK2.